Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Recruiting

Phase 3

REGN7508Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers

Sponsor:

Regeneron Pharmaceuticals

Code:

NCT07493304

Conditions

Venous Thromboembolism (VTE)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

REGN7508

Apixaban

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2026-06-04. This information was provided to ClinicalTrials.gov by Regeneron Pharmaceuticals on 2026-05-29.